| 000 | 01340 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250516072850.0 | ||
| 264 | 0 | _c20120501 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1744-7658 | ||
| 024 | 7 |
_a10.1517/13543784.2012.651457 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBlandini, Fabio | |
| 245 | 0 | 0 |
_aNew pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. _h[electronic resource] |
| 260 |
_bExpert opinion on investigational drugs _cFeb 2012 |
||
| 300 |
_a153-68 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 |
_aDyskinesias _xdrug therapy |
| 650 | 0 | 4 |
_aExcitatory Amino Acid Antagonists _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 |
_aPurinergic P1 Receptor Antagonists _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Glutamate _xmetabolism |
| 650 | 0 | 4 |
_aReceptors, Purinergic P1 _xmetabolism |
| 700 | 1 | _aArmentero, Marie-Therese | |
| 773 | 0 |
_tExpert opinion on investigational drugs _gvol. 21 _gno. 2 _gp. 153-68 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/13543784.2012.651457 _zAvailable from publisher's website |
| 999 |
_c21450247 _d21450247 |
||